We are live on ! Find out more
ANTX icon

AN2 Therapeutics
ANTX

45 hedge funds and large institutions have $41.7M invested in AN2 Therapeutics in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.1% more ownership

Funds ownership: 62.99% → 65.09% (+2.1%)

8% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 13

17% less funds holding

Funds holding: 54 → 45 (-9)

31% less capital invested

Capital invested by funds: $60.9M → $41.7M (-$19.1M)

57% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 14

Holders
45
Holders Change
-9
Holders Change %
-16.67%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
14
Reduced
13
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
+$5.04M
2
FLSM
Frazier Life Sciences Management
California
+$1.67M
3
Millennium Management
Millennium Management
New York
+$1.02M
4
Goldman Sachs
Goldman Sachs
New York
+$466K
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$321K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$4.03M
2
APM
Avidity Partners Management
Texas
-$3.74M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$408K
4
UBS AM
UBS AM
Illinois
-$248K
5
Jane Street
Jane Street
New York
-$192K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$11.9M – – –
OCA
2
Octagon Capital Advisors
New York
$6.92M +$5.04M +2,117,263 +192%
FLSM
3
Frazier Life Sciences Management
California
$4.49M +$1.67M +700,000 +50%
TCM
4
TCG Crossover Management
California
$3.34M – – –
Citadel Advisors
5
Citadel Advisors
Florida
$3.34M -$6.49K -2,725 -0.2%
Janus Henderson Group
6
Janus Henderson Group
United Kingdom
$2.61M -$224 -94 -0%
Vanguard Group
7
Vanguard Group
Pennsylvania
$2.24M -$14.9K -6,242 -0.6%
Millennium Management
8
Millennium Management
New York
$1.13M +$1.02M +429,438 +443%
Adage Capital Partners
9
Adage Capital Partners
Massachusetts
$672K – – –
BlackRock
10
BlackRock
New York
$644K +$20.5K +8,617 +3%
Goldman Sachs
11
Goldman Sachs
New York
$482K +$466K +195,815 +690%
GTC
12
Ghost Tree Capital
New York
$472K – – –
Geode Capital Management
13
Geode Capital Management
Massachusetts
$389K +$3.7K +1,553 +0.9%
Two Sigma Advisers
14
Two Sigma Advisers
New York
$290K +$321K +134,700 New
Two Sigma Investments
15
Two Sigma Investments
New York
$284K +$90.3K +37,920 +40%
BCM
16
Bridgeway Capital Management
Texas
$224K +$186K +78,000 +297%
Alyeska Investment Group
17
Alyeska Investment Group
Illinois
$215K – – –
NCM
18
Nantahala Capital Management
Connecticut
$211K – – –
Squarepoint
19
Squarepoint
New York
$209K +$113K +47,456 +96%
Marshall Wace
20
Marshall Wace
United Kingdom
$207K +$32.4K +13,613 +17%
Walleye Capital
21
Walleye Capital
New York
$199K -$96.1K -40,381 -30%
Acadian Asset Management
22
Acadian Asset Management
Massachusetts
$185K -$182K -76,548 -47%
State Street
23
State Street
Massachusetts
$130K – – –
CRC
24
Curi RMB Capital
Illinois
$98.8K – – –
PCM
25
Prelude Capital Management
New York
$83.7K -$3.29K -1,382 -3%
1
2 3

ANTX Hedge Fund Activity: Q2 2024 in Review

45 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q2 2024, worth a combined $41.7M — down 31% from $60.9M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of ANTX and 6 opened new positions — a net loss of 8 holders — while 13 trimmed existing stakes and 14 added.

The largest buyer was Octagon Capital Advisors, adding an estimated $5.04M. The largest seller was BVF Inc, exiting entirely with an estimated $4.03M sold.

  • 45 institutional investors held AN2 Therapeutics (ANTX) as of Q2 2024, down from 54 in Q1 2024.
  • Funds reported $41.7M of AN2 Therapeutics stock for Q2 2024, down 31% quarter-over-quarter.
  • 6 funds opened new AN2 Therapeutics positions in Q2 2024 and 14 closed out, a net change of -8 holders.
  • The largest AN2 Therapeutics buyer in Q2 2024 was Octagon Capital Advisors, an estimated $5.04M added.
  • The largest AN2 Therapeutics seller in Q2 2024 was BVF Inc, an estimated $4.03M sold.

Based on aggregated 13F filings for Q2 2024.